MicrOs: Bone Architectural Parameters in Postmenopausal Women Affected With Primary Hyperparathyroidism
Study Details
Study Description
Brief Summary
Bone lesions are frequent in primary hyperparathyroidism (PHPT). Conventional measurement by Dual-Energy X-ray Absorptiometry does not provide enough information about the bone impact of excessive parathyroid hormone (PTH) secretion. High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT) assesses separately cortical and trabecular bone sites as well as geometric characteristics of peripheral skeleton. In postmenopausal women, HR-pQCT has shown that decreased microarchitectural parameters are associated with reduced bone strength independently of BMD. The purpose of this study is to characterize the impact of PHPT in cortical and trabecular bone measured by HR-pQCT in postmenopausal women with PHPT followed for one year, in comparison with control postmenopausal women.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Principal objective : To characterize the impact of PHPT in cortical and trabecular bone measured by HR-pQCT in postmenopausal women with PHPT followed for one year, in comparison with control postmenopausal women.
Secondary Objectives : 1) To compare the changes of bone micro-architecture in PHPT women with and without surgery to those of controls 2) To determine if the changes of micro-architecture are related to the severity of PTH secretion and to their changes after surgery 3) to evaluate the association of clinical and biological factors with quantitative bone micro-architectural indices and their changes.
Principal evaluation criteria : Cortical thickness
Secondary evaluation criteria : Quantitative parameters measured with HR-pQCT: trabecular microarchitecture (trabecular bone volume, number, separation, thickness and heterogeneity of trabeculae), cortical microarchitecture (total surface, polar moment of inertia), volumetric density of total, cortical and trabecular bone. Biological parameters: PTH, serum calcium and phosphorus, 25(OH)D, 1,25(OH)2D, biomarkers of bone remodelling, and urinary calcium. BMD measured by DXA. Clinical factor risks of bone loss.
Type of study : Pathophysiological, multicentric, comparative study, with a prospective follow-up of one year in postmenopausal caucasian women affected with PHPT (cases) or non affected by PHPT (controls). Each control will be matched for age, date of menopause, height and weight, to PHPT women.
Study design: assessment of bone and mineral metabolism, DXA and measurement of indices by HR-pQCT at the inclusion. Those tests will be renewed one year after surgery for the PHPT patients and one year after baseline for those without surgery and the controls.
Number of patients needed: 120 postmenopausal women, 60 cases and 60 controls
Total duration of the study: 56 months. Inclusion period : 42 months
Inclusion criteria and principal non-inclusion criteria :
Patients: caucasian women, menopaused for at least one year, aged less than 81 years, affected with symptomatic or asymptomatic PHPT and without any other disease or medication interfering with bone and mineral metabolism. Control population: caucasian women, menopaused for at least one year, aged less than 81 years, without PHPT, diseases or medications interfering with bone and mineral metabolism.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Control Control post menopausal women without PHPT |
Device: HR-pQCT
HR-pQCT to evaluate cortical and trabecular bone
|
Experimental: Experimental Post menopausal women with PHPT followed for one year |
Device: HR-pQCT
HR-pQCT to evaluate cortical and trabecular bone
|
Outcome Measures
Primary Outcome Measures
- Cortical thickness measured by HR-pQCT [one year]
Secondary Outcome Measures
- Three-dimensional evaluation of the cortical and trabecular bone by HR-pQCT [one year]
- Biological and quantitative parameters (assessed by HR-pQCT) [one year]
- Clinical, biological and bone densitometry parameters (assessed by DXA) [one year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients: caucasian women, menopaused for at least one year, aged less than 81 years, affected with symptomatic or asymptomatic PHPT
-
Control population: caucasian women, menopaused for at least one year, aged less than 81 years, without PHPT
Exclusion Criteria:
- diseases or medications interfering with bone and mineral metabolism
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Hopital Lariboisiere | Paris | France | 75010 | |
2 | Hopital Cochin | Paris | France | 75014 | |
3 | Hopital Europeen Georges Pompidou | Paris | France | 75015 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: Gerard MARUANI, MD, Hopital Europeen Georges Pompidou (HEGP)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- P091113